Table 1

Demographic data and baseline and follow-up values of clinical and laboratory characteristics of the study group

Spironolactone (n=58)Placebo (n=55)p Value
CharacteristicBaselineFollow-upp ValueBaselineFollow-upp ValueΔSpironolactone vs ΔPlacebo
Age, years58.8±8.958.8±7.9
Male24 (41)19 (35)
BMI, kg/m235.7±5.235.6±5.20.4135.5±5.035.2±4.90.230.58
Waist circumference, cm106±15106±160.67105±13105±130.360.35
Waist-to-hip ratio0.95±0.120.95±0.120.490.95±0.100.95±0.100.710.48
Systolic blood pressure, mm Hg132±5128±60.001131±6130±60.380.001
Diastolic blood pressure, mm Hg80±477±50.00179±579±40.540.004
Body fat content, kg33.3±7.733.0±7.70.5832.8±6.832.5±6.70.220.84
Android fat deposit, kg3.6±1.03.6±1.10.943.8±0.83.7±0.90.440.28
Gynoid fat deposit, kg8.4±2.38.3±2.40.368.2±2.28.1±2.20.200.81
Android/gynoid fat0.45±0.130.45±0.140.880.49±0.180.48±0.170.660.43
Fasting insulin, mIU/l9.3 (6.4–14.0)11.4 (5.6–17.1)0.396.4 (3.0–8.1)7.3 (4.3–13.7)0.340.86
Fasting glucose, mg/dl97±1097±100.7696±1195±100.680.61
HOMA-IR2.5 (1.6–3.7)2.9 (1.4–4.7)0.361.7 (1.0–2.3)2.1 (1.1–3.6)0.430.83
Creatinine, mg/dl0.87±0.200.85±0.210.250.85±0.170.84±0.140.480.74
Potassium, mmol/l4.2±0.34.5±0.30.00014.3±0.44.3±0.30.450.001
Total cholesterol, mg/dl208±44209±420.85216±44210±400.380.42
Low-density lipoprotein, mg/dl127±38128±360.86134±39131±380.610.61
High-density lipoprotein, mg/dl48±1448±130.7851±1549±150.220.48
Triglycerides, mg/dl161±76166±800.71160±79152±880.560.78
CRP, mg/l3.1 (2.2–4.8)3.4 (2.1–5.1)0.292.8 (2.2–4.1)3.6 (2.3–4.2)0.340.69
PIIINP, μg/l5.2±2.04.7±1.90.045.2±2.05.4±2.90.620.03
PICP, μg/l175±76146±710.001184±75190±790.650.001
TGF-β1, μg/ml29.2±11.326.2±9.20.0425.9±10.126.8±10.20.360.02
Aldosterone, pg/ml52 (27–112)81 (28–160)0.0755 (47–76)55 (41–83)0.680.06
Angiotensin II, pmol/l10.7±4.711.9±7.90.5414.0±5.213.6±6.80.740.25
  • Values are mean±SD, number (%) or median (IQR). ΔPlacebo indicates change in the placebo group during follow-up, and ΔSpironolactone the change in the spironolactone group during follow-up.

  • BMI, body mass index; CRP, C-reactive protein; HOMA-IR, homoeostasis model of assessment–insulin resistance; PICP, procollagen type I C-terminal propeptide; PIIINP, procollagen type III N-terminal propeptide; TGF, transforming growth factor.